Pfizer has applied to the United States Food and Drug Administration (FDA) for authorization for its coronavirus vaccine in children under 5 years of age. If the organism gives the green light, the vaccine may be available this month.
The US authorities are considering the possibility of the emergency use of the anti-vine drug for weeks in the face of the increase in infections in children. In fact, nearly two million positive cases have been reported in the country in the last two weeks.
The concern about this upturn in infection in the younger age brackets is evident and that is why the Biden Administration is considering speeding up the process and approving the new version of the Pfizer vaccine as soon as possible.
According to Pfizer, the vaccine can be given to babies, from 6 months to 5 years. What needs to be studied now is the amount of the drug to be inoculated into these population groups. In early January, the US Centers for Disease Control and Prevention (CDC) recommended “that children 5 to 11 years old with moderate or severe immunosuppression” start receiving an extra dose 28 days after the second shot.
If the FDA finally authorizes the use of the pediatric vaccine, the pharmaceutical consortium will increase its supply of drugs to fight Covid-19. It’s only five days since Pfizer was approved by the European Medicines Agency (EMA) to use its anti-vine pill, Paxlovid.
It is a combination of two antivirals, ritonavir and nirmatrelvir, capable of reducing 89% of hospitalizations in high-risk patients and minimizing the number of deaths from infection. In this regard, the EMA recommends antiviral drugs “in adults who do not require supplemental oxygen and who have an increased risk of the disease becoming severe”.